Recent composition and applications of liposomes in cancer therapy
Source abstract
Abstract
Nanoparticles are major focus of research nowadays. Liposomes are one of the nano-drug delivery system which is focus of research, especially for carrying chemotherapeutic agent for treatment of different cancers of body. Most common method of liposome preparation is thin film hydration method. For cancer therapy, liposome is being used for passive targeting due to leaky vessels of tumors which promotes enhanced and permeability effect and active targeting. Liposome is modified by slight alteration in their composition including long-circulating liposome, fusogenic liposome, immuno-liposome and stimuli-triggering liposome. This review extensively elaborates recent compositions and various applications of liposomes in cancer therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacognosy, Faculty of Pharmaceutical Sciences, Lahore University of Biological & Applied Sciences
Rashid Latif College of Pharmacy, Rashid Latif Medical Complex
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Lahore University of Biological & Applied Sciences
Children Hospital and University of Child Health Sciences
Faculty of Pharmaceutical Sciences, Habib Institute of Health Sciences
References (100+)
Show source-provided references
1. Arora, G. Nanocarrier: A Boom or a Bane in the Medical Industry. Acta Sci. Pharma. Sci. 2019, 3, 08–23.
2. 10.1039/d0nh00605j10.1039/d0nh00605j ↗
3. 10.1007/s10311-018-00841-110.1007/s10311-018-00841-1 ↗
4. 10.3390/molecules2704137210.3390/molecules27041372 ↗
5. 10.1016/j.fbio.2020.10085710.1016/j.fbio.2020.100857 ↗
6. 10.1080/13543776.2019.167976710.1080/13543776.2019.1679767 ↗
7. 10.3389/fbioe.2021.70588610.3389/fbioe.2021.705886 ↗
8. 10.1016/j.addr.2021.01.01910.1016/j.addr.2021.01.019 ↗
9. 10.1016/j.ijpharm.2021.12057110.1016/j.ijpharm.2021.120571 ↗
10. 10.1021/acs.jmedchem.9b0051110.1021/acs.jmedchem.9b00511 ↗
11. 10.3390/nano1110255710.3390/nano11102557 ↗
12. 10.1016/j.addr.2020.07.00210.1016/j.addr.2020.07.002 ↗
13. 10.1007/s12668-022-00941-x10.1007/s12668-022-00941-x ↗
14. 10.1186/s11671-021-03553-810.1186/s11671-021-03553-8 ↗
15. 10.1039/d2bm01703b10.1039/d2bm01703b ↗
16. 10.1016/j.bpj.2014.05.03910.1016/j.bpj.2014.05.039 ↗
17. 10.1016/0001-8686(94)00223-y10.1016/0001-8686(94)00223-y ↗
18. 10.1016/j.ijpharm.2011.03.04910.1016/j.ijpharm.2011.03.049 ↗
19. 10.3389/fphar.2018.0008010.3389/fphar.2018.00080 ↗
20. 10.1016/j.heliyon.2022.e0939410.1016/j.heliyon.2022.e09394 ↗
21. 10.1007/s10973-011-1596-410.1007/s10973-011-1596-4 ↗
22. 10.3109/03639045.2012.66891210.3109/03639045.2012.668912 ↗
23. Allen, T.; Everest, J. Effect of Liposome Size and Drug Release Properties on Pharmacokinetics of Encapsulated Drug in Rats. J. Pharmacol. Exp. Ther. 1983, 226, 539–544.10.1016/S0022-3565(25)21638-X ↗
24. 10.3390/cancers1304067010.3390/cancers13040670 ↗
25. 10.1111/jphp.1309810.1111/jphp.13098 ↗
26. 10.1007/s10311-020-01022-910.1007/s10311-020-01022-9 ↗
27. 10.2174/138161282566619083015531910.2174/1381612825666190830155319 ↗
28. 10.1016/j.msec.2019.11029810.1016/j.msec.2019.110298 ↗
29. 10.3390/cancers1105064010.3390/cancers11050640 ↗
30. 10.1039/D0TB02996C10.1039/D0TB02996C ↗
31. 10.1021/acs.bioconjchem.9b0045610.1021/acs.bioconjchem.9b00456 ↗
32. 10.1016/j.jconrel.2020.02.01910.1016/j.jconrel.2020.02.019 ↗
33. 10.1038/s41578-020-00269-610.1038/s41578-020-00269-6 ↗
34. 10.1126/scirobotics.aaz951910.1126/scirobotics.aaz9519 ↗
35. 10.3390/pharmaceutics1603040010.3390/pharmaceutics16030400 ↗
36. 10.2217/nnm-2019-030810.2217/nnm-2019-0308 ↗
37. 10.1016/j.jddst.2020.10154910.1016/j.jddst.2020.101549 ↗
38. 10.1515/dmpt-2018-003210.1515/dmpt-2018-0032 ↗
39. 10.1016/j.cbi.2019.06.03310.1016/j.cbi.2019.06.033 ↗
40. 10.1615/CritRevTherDrugCarrierSyst.201902635810.1615/CritRevTherDrugCarrierSyst.2019026358 ↗
41. 10.1016/j.ijpharm.2021.12041310.1016/j.ijpharm.2021.120413 ↗
42. 10.1016/j.ijpharm.2020.11926910.1016/j.ijpharm.2020.119269 ↗
43. 10.1021/acsomega.3c0444410.1021/acsomega.3c04444 ↗
44. 10.1186/s11671-019-3164-y10.1186/s11671-019-3164-y ↗
45. 10.1080/08982104.2016.125424210.1080/08982104.2016.1254242 ↗
46. 10.1016/j.ijpharm.2021.12046310.1016/j.ijpharm.2021.120463 ↗
47. 10.1016/j.addr.2022.11439610.1016/j.addr.2022.114396 ↗
48. 10.1016/j.xphs.2017.05.02410.1016/j.xphs.2017.05.024 ↗
49. 10.1016/j.jpba.2018.06.01810.1016/j.jpba.2018.06.018 ↗
50. 10.1080/08982104.2021.188409310.1080/08982104.2021.1884093 ↗
51. 10.1021/acs.langmuir.0c0026210.1021/acs.langmuir.0c00262 ↗
52. 10.1021/acs.langmuir.2c0116910.1021/acs.langmuir.2c01169 ↗
53. 10.3390/ijms1902034610.3390/ijms19020346 ↗
54. 10.1021/acsbiomaterials.2c0149010.1021/acsbiomaterials.2c01490 ↗
55. 10.3389/fphar.2019.0140110.3389/fphar.2019.01401 ↗
56. 10.3390/ijms2106224410.3390/ijms21062244 ↗
57. 10.2174/156720181666619101611271710.2174/1567201816666191016112717 ↗
58. 10.1016/j.biomaterials.2023.12235010.1016/j.biomaterials.2023.122350 ↗
59. 10.1016/j.biopha.2018.11.01110.1016/j.biopha.2018.11.011 ↗
60. 10.2217/imt-2020-025810.2217/imt-2020-0258 ↗
61. 10.1016/j.omtm.2020.07.01510.1016/j.omtm.2020.07.015 ↗
62. 10.1016/j.biopha.2020.11105910.1016/j.biopha.2020.111059 ↗
63. 10.3390/pharmaceutics1309136510.3390/pharmaceutics13091365 ↗
64. 10.1016/j.ijpharm.2018.04.00110.1016/j.ijpharm.2018.04.001 ↗
65. 10.1016/j.colsurfa.2019.12405410.1016/j.colsurfa.2019.124054 ↗
66. 10.1080/08982104.2019.159344910.1080/08982104.2019.1593449 ↗
67. 10.1080/1061186X.2018.150277510.1080/1061186X.2018.1502775 ↗
68. 10.1007/s11095-018-2490-610.1007/s11095-018-2490-6 ↗
69. 10.1021/acs.molpharmaceut.0c0017010.1021/acs.molpharmaceut.0c00170 ↗
70. 10.3390/pharmaceutics1102006910.3390/pharmaceutics11020069 ↗
71. 10.3389/fphar.2022.83816810.3389/fphar.2022.838168 ↗
72. 10.1016/j.jconrel.2018.02.01510.1016/j.jconrel.2018.02.015 ↗
73. 10.1007/s11095-021-02986-110.1007/s11095-021-02986-1 ↗
74. 10.1016/j.eurpolymj.2022.11178110.1016/j.eurpolymj.2022.111781 ↗
75. 10.1016/j.esmoop.2021.10036510.1016/j.esmoop.2021.100365 ↗
76. 10.1080/17425247.2018.151774710.1080/17425247.2018.1517747 ↗
77. 10.1016/j.jconrel.2017.11.02610.1016/j.jconrel.2017.11.026 ↗
78. 10.1016/j.ijpharm.2017.10.02710.1016/j.ijpharm.2017.10.027 ↗
79. 10.1080/08982104.2018.155629310.1080/08982104.2018.1556293 ↗
80. Petrilli, R.; et al. Preparation of Immunoliposomes by Direct Coupling of Antibodies Based on a Thioether Bond. Methods Protocols 2018, 3, 229–237.
81. 10.1016/j.colsurfb.2020.11118510.1016/j.colsurfb.2020.111185 ↗
82. 10.1515/ntrev-2017-015410.1515/ntrev-2017-0154 ↗
83. 10.1039/C9TB02470K10.1039/C9TB02470K ↗
84. 10.2174/138945011766616020814414310.2174/1389450117666160208144143 ↗
85. 10.1080/1061186X.2024.234735610.1080/1061186X.2024.2347356 ↗
86. 10.1016/j.jconrel.2022.08.00110.1016/j.jconrel.2022.08.001 ↗
87. 10.1016/j.addr.2018.10.01210.1016/j.addr.2018.10.012 ↗
88. 10.1016/j.jconrel.2019.09.01810.1016/j.jconrel.2019.09.018 ↗
89. 10.1016/j.ejpb.2018.11.00110.1016/j.ejpb.2018.11.001 ↗
90. 10.2217/nnm-2018-051010.2217/nnm-2018-0510 ↗
91. 10.1016/j.jconrel.2022.05.05610.1016/j.jconrel.2022.05.056 ↗
92. 10.1007/s13346-018-0583-810.1007/s13346-018-0583-8 ↗
93. 10.3389/fonc.2022.80084210.3389/fonc.2022.800842 ↗
94. 10.2147/CMAR.S21323610.2147/CMAR.S213236 ↗
95. 10.1021/acs.molpharmaceut.9b0098810.1021/acs.molpharmaceut.9b00988 ↗
96. 10.1016/j.ejmech.2018.08.03410.1016/j.ejmech.2018.08.034 ↗
97. 10.1016/j.colsurfb.2021.11196710.1016/j.colsurfb.2021.111967 ↗
98. 10.1002/chem.20200052910.1002/chem.202000529 ↗
99. 10.1016/j.drudis.2021.05.01010.1016/j.drudis.2021.05.010 ↗
100. 10.1039/c7cs00663b10.1039/c7cs00663b ↗